Dupilumab
Therapeutic Dupilumab antibody from the original Dupixent® commercial drug.
Reference Standard as Aliquots
Dupixent®
Filters
Sort results
Reset
Apply
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2024.11 |
Dupixent® DE |
12 mg |
Unit: aliquot(s) |
386,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Dupixent ® - Dupilumab Reference Product
| Drug name | Dupixent® | |||
| INN | Dupilumab | |||
| API type | Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. | |||
| Pharmacotherapeutic group | Other dermatological preparations, agents for dermatitis, excluding corticosteroids | |||
| ATC code | D11AH05 | |||
| Target of antibody | IL-13, IL-4 | |||
| General function | Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Dupilumab is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO). | |||
| Short description | ||||
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα). IL-4 and IL-13 are major drivers of human type 2 inflammatory disease, such as atopic dermatitis, asthma, and CRSwNP. Blocking the IL-4/IL-13 pathway with dupilumab in patients decreases many of the mediators of type 2 inflammation. | |||
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In atopic dermatitis clinical trials, treatment with dupilumab was associated with decreases from baseline in concentrations of type 2 immunity biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE and allergen-specific IgE in serum. A reduction of lactate dehydrogenase (LDH), a biomarker associated with AD disease activity and severity, was observed with dupilumab treatment in adults and adolescents with atopic dermatitis. In asthma clinical trials, dupilumab treatment markedly decreased FeNO and circulating concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin in asthma subjects. | |||
| Original license holder | ||||
| Marketing authorisation numbers | EU/1/17/1229/002 | |||
| Marketing authorisation holder | Sanofi-Aventis groupe 54, rue La Boétie 75008 Paris France | |||
| Name of the manufacturer of the biological active substance | REGENERON PHARMACEUTICALS INC. 81 Columbia Turnpike RENSSELAER NEW YORK 12144 UNITED STATES; Regeneron Ireland Designated Activity Company (DAC) Ballycummin Raheen Business Park Limerick Ireland; Genzyme Flanders BVBA Cipalstraat 8, B-2440 Geel Belgium | |||
| Name and address of the manufacturer(s) responsible for batch release | SANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel, 76580 LE TRAIT, FRANCE; Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 Industriepark Hoechst 65926 FRANKFURT AM MAIN GERMANY | |||
| Max shelf life | 3 years | |||
| Storage conditions | 2°C - 8°C | |||
| List of excipients | arginine hydrochloride - histidine - polysorbate 80 (E433) - sodium acetate trihydrate - glacial acetic acid (E260) - sucrose - water for injections |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
